At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 49 enrolled
Drug / intervention
Gleevec +1 moredrug
Likely dose
Gleevec 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Imatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Gleevec and Docetaxel for Prostate Cancer. Completed, enrolled 49 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the effectiveness of two drugs, docetaxel and Gleevec®(also called imatinib), in prostate cancer that no longer responds to hormone therapy. The investigators are interested in finding out if the combination of these two drugs is more effective than docetaxel alone in the treatment of prostate cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2005
First PostedNov 2005
Primary CompletionMar 2009
Study CompletionMar 2014
TodayJul 2026
First PostedNov 9, 2005
Enrollment StartAug 1, 2005
Primary CompletionMar 1, 2009
Study CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 20.6 years ago
Interventions
Gleevecdrug
Imatinib-400mg po qd for 10 days to commence on day 3. On day 0, Docetaxel 60mg/m\^2 administered IV
Docetaxeldrug
60 mg/m\^2 administered IV on day 0